Search results
Showing 121 to 135 of 157 results for pembrolizumab
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
In development [GID-TA11004] Expected publication date: TBC
Awaiting development [GID-TA11343] Expected publication date: TBC
In development [GID-TA10880] Expected publication date: TBC
In development [GID-TA10766] Expected publication date: TBC
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Awaiting development [GID-TA11466] Expected publication date: TBC
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
In development [GID-TA11024] Expected publication date: TBC
In development [GID-TA11401] Expected publication date: TBC
Awaiting development [GID-TA11486] Expected publication date: TBC
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.